Roche Pharma Research and Early Development (pRED)

Our scientists are moving away from simply working toward developing treatments to taking a more holistic approach across diagnostics and pharmaceuticals, so that we may one day chart a new course in Alzheimer’s management, having an impact on the lives of so many throughout the patient journey.

I have seen many research buildings and institutes in my life but nothing compares to the new pRED Center. When I entered the spaces in this building, I could feel my hands start itching - I wanted to be at the bench and starting an experiment. I know that this facility will foster innovation and inspire all of the scientists who come to work here.

The Brainshuttleᵀᴹ technology has created enormous momentum in the industry. We’ve flipped the conversation from if it works to how well it works.

I am very proud to work for Roche because we have this commitment to antibiotics and global health security. You see our people's commitment level and the passion they bring. They raised their hands to be part of this important effort to help save lives around the world.

Changing intrathecal injection to peripheral administration [e.g. intravenous or subcutaneous injection] would mean reducing the treatment burden for patients and could revolutionise their care journey.